• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (NY: MAIA )

    2.910 -0.410 (-12.35%)
    Streaming Delayed Price Updated: 3:48 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 313,999
    Open 3.400
    Bid (Size) 2.910 (5)
    Ask (Size) 2.950 (3)
    Prev. Close 3.320
    Today's Range 2.780 - 3.400
    52wk Range 0.8200 - 5.990
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
    From MAIA Biotechnology, Inc.
    Via Business Wire

    Performance

    YTD
    +144.54%
    +144.54%
    1 Month
    +9.40%
    +9.40%
    3 Month
    +9.40%
    +9.40%
    6 Month
    +0.69%
    +0.69%
    1 Year
    +39.90%
    +39.90%

    More News

    Read More
    MAIA Biotechnology Announces $2.44 Million Private Placement
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
    Via News Direct
    MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
    From MAIA Biotechnology
    Via Business Wire
    MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024
    Via InvestorPlace
    MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy
    Via AB Newswire
    Exposures Product Safety
    MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
    Via Benzinga
    Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
    From MAIA Biotechnology, Inc.
    Via Business Wire
    FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
    Via AB Newswire
    Exposures COVID-19 Product Safety
    MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
    From MAIA Biotechnology, Inc.
    Via Business Wire
    New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
    Via News Direct
    Topics Death
    Exposures Death
    Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
    Via AB Newswire
    MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
    From MAIA Biotechnology, Inc.
    Via Business Wire
    Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
    Via AB Newswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
    From MAIA Biotechnology, Inc.
    Via Business Wire
    MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024
    Via AB Newswire
    MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
    Via AB Newswire
    MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market
    Via News Direct
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.